Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906).

Trial Profile

Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2016 Results published in the Anticancer Research
    • 30 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 09 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top